Compare AstraZeneca plc (AZN) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Msci Inc — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Msci Inc trades at $621.09 (market cap $44.51B). The key difference: AstraZeneca plc is far larger — about 5.7× Msci Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MSCI | |
|---|---|---|
Market Cap | $253.13B | $44.51B |
Sector | Health | Financials |
52-Week High | $209.48 | $643.83 |
52-Week Low | $137.44 | $511.84 |
Enterprise Value | $279.37B | $50.68B |
Dividend Yield | 1.92% | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MSCI trades at $620.23, up 2.57% with bullish technical signals and strong earnings beats. The company shows robust fundamentals with 2025 revenue of $3.13B and net income of $1.20B, supported by high margins. Recent news highlights strategic partnerships with UBS and acquisitions to enhance private markets and climate risk capabilities, reinforcing growth prospects amid positive analyst sentiment.
Outlook remains positive with a consensus price target of $718.14, though elevated P/E of 35.42 and high debt levels pose valuation and financial risks. Earnings growth and strategic expansions are key catalysts, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
